MDT

95.08

-0.41%↓

VEEV

280.96

-4.44%↓

A

141.06

-0.77%↓

HQY

91.29

-1.17%↓

TLRY

1.5

-5.06%↓

MDT

95.08

-0.41%↓

VEEV

280.96

-4.44%↓

A

141.06

-0.77%↓

HQY

91.29

-1.17%↓

TLRY

1.5

-5.06%↓

MDT

95.08

-0.41%↓

VEEV

280.96

-4.44%↓

A

141.06

-0.77%↓

HQY

91.29

-1.17%↓

TLRY

1.5

-5.06%↓

MDT

95.08

-0.41%↓

VEEV

280.96

-4.44%↓

A

141.06

-0.77%↓

HQY

91.29

-1.17%↓

TLRY

1.5

-5.06%↓

MDT

95.08

-0.41%↓

VEEV

280.96

-4.44%↓

A

141.06

-0.77%↓

HQY

91.29

-1.17%↓

TLRY

1.5

-5.06%↓

Search

MannKind Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

5.32 0.38

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.2

Max

5.35

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-12M

668K

Pardavimai

-1.8M

77M

P/E

Sektoriaus vid.

46.364

36.442

Pelno marža

0.873

Darbuotojai

403

EBITDA

-17M

9.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+102.1% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

373M

1.6B

Ankstesnė atidarymo kaina

4.94

Ankstesnė uždarymo kaina

5.32

Naujienos nuotaikos

By Acuity

29%

71%

86 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-16 21:10; UTC

Pagrindinės rinkos jėgos

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

2025-10-16 19:03; UTC

Įsigijimai, susijungimai, perėmimai

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

2025-10-16 17:58; UTC

Įsigijimai, susijungimai, perėmimai

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

2025-10-16 17:12; UTC

Uždarbis

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

2025-10-16 17:12; UTC

Įsigijimai, susijungimai, perėmimai

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

2025-10-16 16:59; UTC

Įsigijimai, susijungimai, perėmimai

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

2025-10-16 23:44; UTC

Rinkos pokalbiai

Gold Climbs Amid Safe-Haven Demand -- Market Talk

2025-10-16 23:42; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

2025-10-16 23:42; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-16 22:15; UTC

Uždarbis

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

2025-10-16 22:15; UTC

Uždarbis

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

2025-10-16 22:15; UTC

Uždarbis

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

2025-10-16 22:02; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-16 22:02; UTC

Rinkos pokalbiai

Santos Drifts Into 'Oversold Territory' -- Market Talk

2025-10-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-16 20:50; UTC

Rinkos pokalbiai
Uždarbis

Health Care Roundup: Market Talk

2025-10-16 20:23; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-16 20:23; UTC

Rinkos pokalbiai

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

2025-10-16 20:20; UTC

Uždarbis

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

2025-10-16 20:08; UTC

Įsigijimai, susijungimai, perėmimai

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

2025-10-16 19:37; UTC

Įsigijimai, susijungimai, perėmimai

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

2025-10-16 19:26; UTC

Uždarbis

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

2025-10-16 19:24; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

2025-10-16 19:23; UTC

Rinkos pokalbiai

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

2025-10-16 19:23; UTC

Uždarbis

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

2025-10-16 18:35; UTC

Rinkos pokalbiai
Uždarbis

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

2025-10-16 18:31; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-16 18:31; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-16 18:31; UTC

Rinkos pokalbiai

Charles Schwab Readies Spot Crypto Trading -- Market Talk

2025-10-16 16:57; UTC

Rinkos pokalbiai

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

102.1% į viršų

12 mėnesių prognozė

Vidutinis 10.57 USD  102.1%

Aukščiausias 15 USD

Žemiausias 8 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.079 / 4.323Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

86 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat